Review of 2009: Buy, sell and grow – an eventful year for Covidien
This article was originally published in Clinica
Executive Summary
In 2009, no medtech firm was more active in the M&A market than Covidien. Along with a relocation to Ireland and having to face the challenges of an ongoing imaging isotope shortage, it has been a busy year for the firm. Joseph Harvey spoke with chairman, president and CEO Richard Meelia about where 2009 has left Covidien in the medtech hierarchy
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals